Evidence map›Paper›PMID 34612543›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2022

Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.

Lasse Pihlstrøm, Chun C Fan, Oleksandr Frei, Manuela Tan, Roshan A Karunamuni, Cornelis Blauwendraat, Sara Bandres-Ciga, Ziv Gan-Or, Donald G Grosset, International Parkinson's Disease Genomics Consortium (IPDGC) and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Parkinson's disease therapy: what lies ahead?Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Lasse PihlstrømDepartment of Neurology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-7635-8645
Chun C FanDepartment of Cognitive Science, University of California San Diego, La Jolla, California, USA.
Oleksandr FreiNORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Manuela TanDepartment of Neurology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5835-669X
Roshan A KarunamuniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.
Cornelis BlauwendraatMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Sara Bandres-CigaMolecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Ziv Gan-OrMontreal Neurological Institute, McGill University, Montreal, Québec, Canada.ORCID 0000-0003-0332-234X
Donald G GrossetDepartment of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
International Parkinson's Disease Genomics Consortium (IPDGC)
Anders M DaleDepartment of Cognitive Science, University of California San Diego, La Jolla, California, USA.
Tyler M SeibertCenter for Multimodal Imaging and Genetics, School of Medicine, University of California San Diego, La Jolla, California, USA.
Ole A AndreassenNORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Oslo University Hospital · NONational Institutes of Health · USMontreal Neurological Institute and Hospital · CAQueen Elizabeth University Hospital · GBUniversity of California San Diego · USUniversity of California System · US

Funding

Intramural NIH HHS Z99 AG999999Parkinson's UK J-1101
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is a highly age-related disorder, where common genetic risk variants affect both disease risk and age at onset. A statistical approach that integrates these effects across all common variants may be clinically useful for individual risk stratification. A polygenic hazard score methodology, leveraging a time-to-event framework, has recently been successfully applied in other age-related disorders.

objectivesWe aimed to develop and validate a polygenic hazard score model in sporadic PD.

methodsUsing a Cox regression framework, we modeled the polygenic hazard score in a training data set of 11,693 PD patients and 9841 controls. The score was then validated in an independent test data set of 5112 PD patients and 5372 controls and a small single-study sample of 360 patients and 160 controls.

resultsA polygenic hazard score predicts the onset of PD with a hazard ratio of 3.78 (95% confidence interval 3.49-4.10) when comparing the highest to the lowest risk decile. Combined with epidemiological data on incidence rate, we apply the score to estimate genetically stratified instantaneous PD risk across age groups.

conclusionsWe demonstrate the feasibility of a polygenic hazard approach in PD, integrating the genetic effects on disease risk and age at onset in a single model. In combination with other predictive biomarkers, the approach may hold promise for risk stratification in future clinical trials of disease-modifying therapies, which aim at postponing the onset of PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Parkinson DiseaseBiomarkersHumansIncidenceMultifactorial InheritanceRisk FactorsBiomarkersage at onsetgeneticsParkinson's diseasepolygenic scoreprediction

Identifiers

PMID34612543
PMCPMC9843635
OpenAlexW3202200735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.